Skip to main content

Table 1 Laboratories performing PCR genotyping with assessment of PCR use-effectiveness in 17 in vivo studies of antimalarial drug efficacy

From: Different methodological approaches to the assessment of in vivo efficacy of three artemisinin-based combination antimalarial treatments for the treatment of uncomplicated falciparum malaria in African children

Year Country
& Site
Laboratory Method used N Unresolved
by PCR
n
Resolved
by PCR
n
PCR Use-
effectiveness
[95%CI]
     recurr.
after
day14
   
2002 Zambia, Maheba Rouen France msp2 43 3 40 93.0
        [80.9–98.5]
2003 Angola, Kuito IMT Antwerp msp1+msp2 8 0 8 100.0
        [63.1–100.0]
2003 DRC, Boende IMT Antwerp msp1+msp2 +glurp 78 10 68 87.2
        [77.7–93.7]
2003 S Sudan, Nuba Wellcome Trust/Medical College of Malawi msp1+msp2 54 15 39 72.2
        [58.3–83.5]
2003 Uganda, Amudat Epicentre Mbarara msp1+msp2 +glurp 73 4 69 94.5
        [86.6–98.5]
2003 Uganda, Jinja UCSF msp2 27 2 25 92.6
        [75.7–99.1]
2003 Uganda, Kampala UCSF msp2 14 0 14 100.0
        [76.8–100.0]*
2004 Angola, Caala Mbarara University msp1+msp2 +glurp 6 2 4 66.7
        [22.3–95.7]
2004 Congo, Kindamba SMRU msp1+msp2 +glurp 60 24 36 60.0
        [46.5–72.4]
2004 DRC, Kabalo Epicentre Mbarara msp1+msp2 +glurp 10 1 9 90.0
        [55.5–99.7]
2004 Guinea, Dabola Epicentre Mbarara msp1+msp2 +glurp 14 1 13 92.9
        [66.1–99.8]
2004 Sierra Leone, Kailahun Paris, Avicenne msp1+msp2 65 1 64 98.5
        [91.7–100.0]
2004 Uganda, Apac UCSF msp2 76 3 73 96.0
        [88.9–99.2]
2004 Uganda, Arua UCSF msp2 61 4 57 93.4
        [84.1–98.2]
2004 Uganda, Tororo UCSF msp2 120 3 117 97.5
        [92.9–99.5]
2005 Burkina Faso, Bobo-Dioulasso UCSF msp1 +msp2 + 4 microsatellites 24 0 24 100
        [85.7–100]*
2005 Uganda, Tororo UCSF msp1+msp2 209 4 205 98.1
        [95.2–99.5]
  TOTAL    942 77 865  
  Weighted average [CI 95]       91.8 [89.9–93.4]
  Median [range]       93.4 [60–100]
  1. Use-effectiveness = number of children with parasite recurrence resolved by PCR/total number of children with recurrences after day 14.
  2. * One sided 97.5% CIs have been calculated
  3. IMT Institut de Médecine Tropicale Antwerp
  4. KEMRI Kenya Medical Research Institute
  5. SMRU Shoklo Malaria Research Unit, Thailand
  6. UCSF University of California, San Francisco
  7. msp1 merozoite surface protein 1
  8. msp2 merozoite surface protein 2
  9. glurp glutamate rich protein